Liraglutide: a once-daily human glucagon-like peptide-1 analogue.

作者信息

Aimaretti G

机构信息

Endocrinology, Department of Experimental and Clinical Medicine, University A. Avogadro del Piemonte Orientale, 28100 Novara, Italy.

出版信息

J Endocrinol Invest. 2009 Sep;32(8):701-3. doi: 10.1007/BF03345744.

DOI:10.1007/BF03345744

PMID:19942822

Abstract

摘要

相似文献

Liraglutide: a once-daily human glucagon-like peptide-1 analogue.

J Endocrinol Invest. 2009 Sep;32(8):701-3. doi: 10.1007/BF03345744.

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

Clin Ther. 2009 Nov;31(11):2472-88. doi: 10.1016/j.clinthera.2009.11.034.

[Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].

Nihon Yakurigaku Zasshi. 2010 Oct;136(4):233-41. doi: 10.1254/fpj.136.233.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z.

Investigational treatments for Type 2 diabetes mellitus: exenatide and liraglutide.

Expert Opin Investig Drugs. 2006 Aug;15(8):887-95. doi: 10.1517/13543784.15.8.887.

Liraglutide in the management of type 2 diabetes.

Drug Des Devel Ther. 2010 Oct 22;4:279-90. doi: 10.2147/DDDT.S10180.

C-peptide response to glucagon challenge is correlated with improvement of early insulin secretion by liraglutide treatment.

Diabetes Res Clin Pract. 2012 Dec;98(3):e32-5. doi: 10.1016/j.diabres.2012.09.036. Epub 2012 Oct 13.

[Protective effects of glucagon-like peptide-1 on beta-cells: preclinical and clinical data].

G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):5-9. doi: 10.1714/985.10684.

Treatment evaluation of liraglutide in type 2 diabetes.

Expert Opin Biol Ther. 2012 Nov;12(11):1551-6. doi: 10.1517/14712598.2012.716823. Epub 2012 Aug 16.

Liraglutide.

Nat Rev Drug Discov. 2010 Apr;9(4):267-8. doi: 10.1038/nrd3148.

引用本文的文献

Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.

Sci Rep. 2025 Aug 12;15(1):29520. doi: 10.1038/s41598-025-12728-7.

A Plethora of GLP-1 Agonists: Decisions About What to Use and When.

Curr Diab Rep. 2016 Dec;16(12):120. doi: 10.1007/s11892-016-0823-6.

One-year treatment with liraglutide improved renal function in patients with type 2 diabetes: a pilot prospective study.

Endocrine. 2015 Dec;50(3):620-6. doi: 10.1007/s12020-014-0519-0. Epub 2015 Jan 9.

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus.

Diabetes Metab Syndr Obes. 2010 May 17;3:165-72. doi: 10.2147/dmsott.s7493.

本文引用的文献

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).

Diabet Med. 2009 Mar;26(3):268-78. doi: 10.1111/j.1464-5491.2009.02666.x.

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

Diabetes Care. 2009 Jul;32(7):1224-30. doi: 10.2337/dc08-2124. Epub 2009 Mar 16.

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Diabetes. 2009 Apr;58(4):975-83. doi: 10.2337/db08-1193. Epub 2009 Jan 16.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Diabetes Care. 2009 Jan;32(1):84-90. doi: 10.2337/dc08-1355. Epub 2008 Oct 17.

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.

Lancet. 2009 Feb 7;373(9662):473-81. doi: 10.1016/S0140-6736(08)61246-5. Epub 2008 Sep 24.

Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.

Diabetes Care. 2007 Jun;30(6):1608-10. doi: 10.2337/dc06-2593. Epub 2007 Mar 19.

The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro.

Biochem Biophys Res Commun. 2005 May 6;330(2):577-84. doi: 10.1016/j.bbrc.2005.03.013.

One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.

Diabetes. 2004 May;53(5):1187-94. doi: 10.2337/diabetes.53.5.1187.

The endocrine pancreas in non-diabetic rats after short-term and long-term treatment with the long-acting GLP-1 derivative NN2211.

APMIS. 2003 Dec;111(12):1117-24. doi: 10.1111/j.1600-0463.2003.apm1111207.x.

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics.

Br J Pharmacol. 2003 Sep;140(1):123-32. doi: 10.1038/sj.bjp.0705397. Epub 2003 Jul 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验